Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Versailles Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02767063
- Locations
- ๐ซ๐ท
CHU Estaing, Clermont-Ferrand, France
๐ซ๐ทFranck NICOLINI, Lyon, France
๐ซ๐ทCHU de LIMOGES, Limoges, France
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
- Conditions
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 998
- Registration Number
- NCT02718417
- Locations
- ๐บ๐ธ
Investigational Drug Service, Emory University Clinic, Atlanta, Georgia, United States
๐บ๐ธEmory University Hospital Midtown, Atlanta, Georgia, United States
๐บ๐ธUniversity Hospital, The Cancer Center, Newark, New Jersey, United States
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2022-06-09
- Target Recruit Count
- 499
- Registration Number
- NCT02625610
- Locations
- ๐บ๐ธ
University of Rochester, Rochester, New York, United States
๐ฆ๐บFiona Stanley Hospital, Murdoch, Western Australia, Australia
๐ซ๐ทCentre Georges Franรงois Leclerc, Dijon cedex, Cรดte-d'Or, France
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2020-11-24
- Target Recruit Count
- 371
- Registration Number
- NCT02625623
- Locations
- ๐บ๐ธ
Advanced Medical Specialties 8940 North Kendall Drive, Suite 300E, Miami, Florida, United States
๐บ๐ธNew York Oncology Hematology, P.C. 400 Patroon Creek Blvd, Suite 1, Albany, New York, United States
๐บ๐ธOncology Specialists, S.C. 1700 Luther Ln, Ste 2200, Park Ridge, IL 60068 7900 Milwaukee Ave, Ste 16, Niles, Illinois, United States
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT02603419
- Locations
- ๐ฎ๐น
Az. Ospedaliera-Univers. di Bologna Policlinico S.Orsola-Malpighi, Bologna, BO, Italy
๐บ๐ธCity of Hope, Duarte, California, United States
๐ฎ๐นIstituto Clinico Humanitas U.O. Oncologia ed Ematologia, Rozzano, Milano, Italy
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT02584829
- Locations
- ๐บ๐ธ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
- Conditions
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT02584634
- Locations
- ๐บ๐ธ
Ophthalmic Consultants of Boston Inc (OCB), Boston, Massachusetts, United States
๐ฏ๐ตAichi cancer center central hospital, Nagoya, Aichi, Japan
๐ช๐ธHospital Universitari de la Vall d'Hebron, Barcelona, Spain
Avelumab in First-line NSCLC (JAVELIN Lung 100)
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2024-03-20
- Target Recruit Count
- 1214
- Registration Number
- NCT02576574
- Locations
- ๐ง๐ช
A.Z. Klina, Brasschaat, Belgium
๐ฆ๐บFiona Stanley Hospital, Murdoch, Western Australia, Australia
๐บ๐ธArizona Center for Cancer Care, Surprise, Arizona, United States
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
- Conditions
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 409
- Registration Number
- NCT02554812
- Locations
- ๐บ๐ธ
Florida Cancer Specialists, Sarasota, Florida, United States
๐ฆ๐บThe Mater Hospital, North Sydney, New South Wales, Australia
๐บ๐ธMount Sinai Comprehensive Cancer Center - Aventura, Aventura, Florida, United States
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2020-08-03
- Target Recruit Count
- 792
- Registration Number
- NCT02395172
- Locations
- ๐จ๐ด
Hemato Oncologos S.A., Cali, Colombia
๐บ๐ธHealing Hands Oncology and Medical Care, Lawndale, California, United States
๐ฆ๐ทHospital Universitario Austral, Pilar, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.